Arcutis Biotherapeutics, Inc. ARQT Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Arcutis Biotherapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed October 28, 2025, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s return on equity?
- Arcutis Biotherapeutics, Inc. (ARQT) reported return on equity of -28.2% in Q3 2025.
- How has Arcutis Biotherapeutics, Inc.'s return on equity changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s return on equity increased by 85.4% year-over-year, from -192.3% to -28.2%.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s return on equity?
- Over 3 years (2021 to 2024), Arcutis Biotherapeutics, Inc.'s return on equity has grown at a 16.1% compound annual growth rate (CAGR), from -72.6% to -113.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.